摘要
AD的鉴别诊断任因与其它痴呆的重叠特征而存在困难。用于AD鉴别诊断的生物标记物可以提高该病的诊断价值并确保恰当治疗。该研究目的在于评价两个作为AD鉴别诊断血清生物标记物的新抗原表位Tau片断的潜力。 新抗原表位Tau片断在一群代表性的患有AD,MCI,其它痴呆或非痴呆向关的记忆力减退的受试者中进行评价。两种新抗原表位Tau片断是ADAM10产生的片断(Tau-A)和半胱天冬酶3产生的片断(Tau-C)。该研究已分别用两种竞争性ELISA检测Tau-A和Tau-C测量这些片断的血清水平。 Tau-A和Tau-C能将患有AD和MCI的受试者与其它痴呆患者区分(p < 0.0042 和p < 0.05),且Tau-A能将AD和MCI患者与非痴呆相关的记忆力减退受试者区分(p <0.05)。Tau-A与CSF生物标记物t-Tau和p-Tau相比,显示了明显更高的对AD和MCI受试者与其它痴呆患者的区分。Tau-A 区分AD和MCI受试者与其它痴呆患者的能力被与CSF Aβ1-42, t-Tau/Aβ1-42 和 p-Tau/Aβ1-42比较。当CSF生物标记物与年龄和BMI与Tau-A联合使用时(AUC = 0.87,95% CI: 0.75-0.94)(p < 0.0001),诊断组间的区分度显著提高。结论是,该研究表明血清中检测出的新抗原表位Tau片断能为AD鉴别诊断提供指导。
关键词: 老年痴呆,鉴别诊断,血清生物标记物,Tau片断。
Current Alzheimer Research
Title:Serum Fragments of Tau for the Differential Diagnosis of Alzheimer's Disease
Volume: 12 Issue: 9
Author(s): D. Inekci, K. Henriksen, T. Linemann, M.A. Karsdal, A. Habib, C. Bisgaard, F.B. Eriksen and O.J. Vilholm
Affiliation:
关键词: 老年痴呆,鉴别诊断,血清生物标记物,Tau片断。
摘要: Differential diagnosis of AD is still a challenge due to overlapping features with other types of dementia. Biomarkers for the differential diagnosis of AD can improve the diagnostic value of the disease and ensure an appropriate treatment of patients. The aim of this study was to evaluate the potential of two neo-epitope fragments of Tau as serum biomarkers for differential diagnosis of AD.
The neo-epitope fragments of Tau were assessed in a cross-sectional cohort of subjects with AD, MCI, other dementias or subjects with non-dementia related memory complaints. The two Tau neo-epitope fragments were an ADAM10-generated fragment (Tau-A) and a caspase-3-generated fragment (Tau-C). The serum levels of the fragments were measured by two competitive ELISAs detecting Tau-A and Tau-C, respectively.
Tau-A and Tau-C were able to separate subjects with AD and MCI from those with other dementias (p < 0.0042 and p < 0.05), and Tau-A could also discriminate between AD and MCI patients and subjects with non-dementia related memory complaints (p < 0.05). Tau-A showed a significantly greater discrimination between AD and MCI subjects and patients with other dementias when compared to CSF biomarkers t-Tau and p-Tau. The ability of Tau-A to differentiate between AD and MCI from other dementias was comparable with CSF Aβ1-42, t-Tau/Aβ1-42 and p-Tau/Aβ1-42. The separation between the diagnostic groups was significantly improved when the CSF biomarkers as well as age and BMI were used in combination with Tau-A (AUC = 0.87, 95% CI: 0.75-0.94) (p < 0.0001). In conclusion, this study shows that a neoepitope fragment of Tau detected in serum can provide guidance on the differential diagnosis of AD.
Export Options
About this article
Cite this article as:
D. Inekci, K. Henriksen, T. Linemann, M.A. Karsdal, A. Habib, C. Bisgaard, F.B. Eriksen and O.J. Vilholm , Serum Fragments of Tau for the Differential Diagnosis of Alzheimer's Disease, Current Alzheimer Research 2015; 12 (9) . https://dx.doi.org/10.2174/1567205012666150710111211
DOI https://dx.doi.org/10.2174/1567205012666150710111211 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dietary Lipids and Alzheimer’s Disease
Current Alzheimer Research Recent Advances in Potential Therapeutic Drugs for Cognitive Impairment in Schizophrenia
Current Psychiatry Reviews Update of QSAR & Docking Studies of the GSK-3 Inhibitors
Current Bioinformatics Do mtDNA Mutations Participate in the Pathogenesis of Sporadic Parkinsons Disease?
Current Genomics Is Amyloid Binding Alcohol Dehydrogenase a Drug Target for Treating Alzheimer’s Disease?
Current Alzheimer Research Toll-Like Receptors and Inflammation in the CNS
Current Drug Targets - Inflammation & Allergy Statins as Either Immunomodulators or Anti-Cancer Drugs: Functional Activities on Tumor Stromal Cells and Natural Killer Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Modulation of Apoptosis in Acute Ischemic Stroke as Treatment Challenges
Current Immunology Reviews (Discontinued) Analytical Tools for the Determination of Antioxidants and Antioxidant Capacity in Biological Samples, Principles and Applications
Current Organic Chemistry Neuropsychiatric and Cognitive Symptoms in Spinocerebellar Ataxia: Relationship to Neuropathological Differences
Current Psychiatry Reviews Host Neuro- Immuno-Endocrine Responses In Periodontal Disease
Current Pharmaceutical Design Molecular Hydrogen as a Neuroprotective Agent
Current Neuropharmacology Patented In Vitro Blood-Brain Barrier Models in CNS Drug Discovery
Recent Patents on CNS Drug Discovery (Discontinued) Cholinergic System and Neuroinflammation: Implication in Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Heart Valve Lesions In The Antiphospholipid Syndrome
Current Rheumatology Reviews Effects of Yokukansan, a Japanese Kampo Medicine for Symptoms Associated Autism Spectrum Disorder
CNS & Neurological Disorders - Drug Targets Mitochondrial Deficits Accompany Cognitive Decline Following Single Bilateral Intracerebroventricular Streptozotocin
Current Alzheimer Research A Cyclooxygenase-2 Inhibitor Reduces Vascular Wall Thickness and Ameliorates Cognitive Impairment in a Cerebral Small Vessel Diseases Rat Model
Current Alzheimer Research Antihyperlipidemic and Antiobesity Potential of <i>Aquilaria agallocha</i> and <i>Borago officinalis</i> in Fixed-Dose Combination; A Contingent Probe with Atorvastatin and Orlistat
Current Bioactive Compounds Ginseng for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Current Topics in Medicinal Chemistry